The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
Clinical trial NCT05732129 · UNKNOWN
Trial details
- NCT number
- NCT05732129
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-01
- Primary completion
- 2023-11-30
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.